Skip to main content
. Author manuscript; available in PMC: 2021 Jul 28.
Published in final edited form as: Ann Surg Oncol. 2020 Jun 2;27(11):4122–4130. doi: 10.1245/s10434-020-08648-7

TABLE 2.

Pretreatment immune profiles and treatment response of patients receiving neoadjuvant immunotherapy

Tex percentage (average ± SD) Treg percentage (average ± SD) ORR patients (%)
Neoadjuvant cohort 25.7 ± 14.5 18.4 ± 11.2 16 (94.1)

Tex, exhausted T lymphocytes, CD8+PD-1+CTLA-4+; Treg, regulatory T lymphocytes, CD4+CD25+Foxp3+; ORR, overall response rate to treatment as evaluated by RECIST v1.1